To minimize these limitations and enhance the study quality, we prospectively assessed the validated PD-L1 (SP142) IHC analyses in the tumor samples at diagnosis; we included patients who were accurately staged based on FDG-PET/CT, brain imaging, and chest CT. The gene discussed is CD274; the disease is neoplasm.